About Adagene Company
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
Adagene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 09/01/2023 267.65% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/21/2023 267.65% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)
Adagene Reports 1H Results